Bloomberg: Φορολογικός παράδεισος η Γαλλία για τις εταιρείες τεχνολογίας

epa01504667 Dr Stephan Schilling observes the results of a treatment study of mice on the behaviour and the brain's neuropathology at the department of enzymology at the biopharmaceutical company 'Probiodrug mbH' in Halle, Germany, 29 September 2008. With a new type of agent, German researchers were able to contain the Alzheimer's disease symptoms of laboratory animals. The agent prevented the development of the typical protein deposition in the brain of the laboratory mice by 80 per cent, as the researchers explained to German radio station MDR Info. The next few years will show if the new agent is suitable as a new Alzheimer drug. The researchers described their new discovery in an online publishment of the specialist magazine 'Nature Medicine' on 29 September 2008. EPA/Waltraud Grubitzsch {{ (File:INT6887461.jpg)(Country:Germany)(City:Halle)(Object:GERMANY ALZHEIMER RESEARCH) }}